3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
14
Thoracic
6
Gynecologic
6
Genitourinary
5
Gastrointestinal
4
Sarcoma
3
Dermatologic
3
Head & Neck
2
Plasma cell
1
Other solid neoplasm
1
Endocrine
1
CNS
1
Conditions
Neuroblastoma
17
Glioblastoma
11
Melanoma
5
Brain Neoplasms
5
Rhabdoid Tumor
4
Osteosarcoma
4
Lymphoma
4
Glioma
4
Sarcoma, Ewing
3
Rhabdomyosarcoma
3
Recurrence
3
Ovarian Neoplasms
3
Neoplasm Metastasis
3
Leukemia, Myeloid, Acute
3
Carcinoma, Hepatocellular
3
Breast Neoplasms
3
Wilms Tumor
2
Prostatic Neoplasms
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Pinealoma
2
Neurofibromatosis 1
2
Neuroectodermal Tumors, Primitive
2
Neoplasms, Germ Cell and Embryonal
2
Multiple Myeloma
2
Meningioma
2
Medulloblastoma
2
Lymphoma, Non-Hodgkin
2
Liver Neoplasms
2
Leukemia, Myelomonocytic, Juvenile
2
Hepatoblastoma
2
Interventions
pembrolizumab
3
Trastuzumab
2
Irinotecan
2
Cyclophosphamide
2
vocimagene amiretrorepvec
1
veliparib
1
sacituzumab govitecan
1
paclitaxel-Angiopep-2 conjugate
1
lenvatinib
1
irinotecan sucrosofate
1
iniparib
1
fludarabine
1
depatuxizumab mafodotin
1
cabozantinib
1
bintrafusp alfa protein, human
1
aldesleukin
1
Platinum
1
Nivolumab
1
NVP-BKM120
1
N-(2,3-dihydroxypropyl)-1-((2-fluoro-4-iodophenyl)amino)isonicotinamide
1
Metformin
1
Mebendazole
1
Ipilimumab
1
Interleukin-2
1
Flucytosine
1
Doxycycline
1
Cisplatin
1
Capecitabine
1
Atorvastatin
1
7-hydroxystaurosporine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Triple Negative Breast Neoplasms
×
fludarabine
×
CNS
×
Clear all
NCT07523529
2026-04-13
SELECT-2CAR
Beijing Biotech
Phase 1/2
Recruiting
72 enrolled